OakChart

Smith & Nephew plc ADR

SNNHealthcare·Medical Devices·United Kingdom·Large·NYSE·Nov 11 • 10:11 AM ET

30.84-0.08 (-0.26%)
2026-11-11 16:11 CET
Market cap
12,940.55 USD m
Revenue, TTM
6,286.69 USD m
Net income, TTM
633.63 USD m
Free cash flow, TTM
849.38 USD m
EPS diluted, TTM
1.47
P/E
21.03
Compare

Price

SNN against its 20, 50 and 200-day averages
2050200beat
26.0028.0030.0032.0034.002.2M4.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SNNclose 30.8420-day 30.3450-day 28.63200-day 30.9930.84

16.9% under 37.09 on 27 Feb 2026. Last 15 sessions, 11.5% high to low

Profile

SNN
52-week range, 43% of the way up
26.1237.09

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Employees18362
IPONov 16, 1999
Beta0.53
ATR, 14d0.71
Rel volume0.73
Short float1.05%
Insider own0.06%
Inst own13.23%

Snapshot

6 groups

Valuation

Index-
Market Cap12.91B
Enterprise Value15.95B
Income633.63M
Sales6.29B
Book/sh12.26
Cash/sh1.81
Dividend Est.0.78 (2.54%)
Dividend TTM0.79 (2.57%)
Dividend Ex-DateOct 02, 2026
Dividend Gr. 3/5Y0.91% 0.54%
Payout52.04%
Employees18362
IPONov 16, 1999

Ratios

P/E21.03
Forward P/E13.35
PEG1.65
P/S2.05
P/B2.51
P/C17.02
P/FCF15.20
EV/EBITDA9.55
EV/Sales2.54
Quick Ratio1.11
Current Ratio2.14
Debt/Eq0.73
LT Debt/Eq0.62
Option/ShortYes / Yes

Earnings

EPS (ttm)1.47
EPS next Y2.31
EPS next Q0.66
EPS this Y4.83%
EPS next Y8.03%
EPS next 5Y8.07%
EPS past 3/5Y41.40% 6.97%
Sales past 3/5Y5.84% 6.10%
EPS Y/Y TTM31.02%
Sales Y/Y TTM5.26%
EPS Q/Q4.72%
Sales Q/Q3.61%
EarningsAug 04 BMO
EPS/Sales Surpr.0.72% -10.44%

Ownership

Insider Own0.06%
Insider Trans0.00%
Inst Own13.23%
Inst Trans-6.63%
ROA5.82%
ROE11.80%
ROIC7.51%
Gross Margin68.21%
Oper. Margin17.05%
Profit Margin10.08%
SMA201.63%
SMA507.73%
SMA200-0.47%
Trades-

Technical

Shs Outstand424.66M
Shs Float418.28M
Short Float1.05%
Short Ratio2.90
Short Interest4.40M
52W High37.09 -16.85%
52W Low26.12 18.07%
Volatility2.65% 1.84%
ATR (14)0.71
RSI (14)58.20
Beta0.53
Rel Volume0.73
Avg Volume1.52M
Volume166,321

Performance

Perf Week-4.99%
Perf Month10.70%
Perf Quarter2.42%
Perf Half Y3.42%
Perf YTD-6.00%
Perf Year-7.33%
Perf 3Y25.83%
Perf 5Y-11.78%
Perf 10Y12.10%
Recom3.00
Target Price32.32
Prev Close30.92
Price30.84
Change %-0.26%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 08, 2026DowngradeBBofA SecuritiesBuy → Neutral
Sep 02, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight
Aug 31, 2026InitiatedBBTIG ResearchNeutral
Aug 06, 2026DowngradeJJP MorganOverweight → Neutral
Aug 05, 2026DowngradeBBarclaysEqual Weight → Underweight
Jun 04, 2026DowngradeKKeplerBuy → Hold
Dec 15, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform
Oct 14, 2025DowngradeBBernsteinOutperform → Mkt Perform$37.50+21.6%
Apr 25, 2025DowngradeHHSBC SecuritiesBuy → Hold
Mar 12, 2025DowngradeUUBSBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
ZBHZimmer Biomet Holdings Inc20.19B
SYKStryker Corp120.92B
GMEDGlobus Medical Inc9.91B
CNMDConmed Corp1.53B
ENOVEnovis Corp1.66B
IARTIntegra Lifesciences Holdings Corp1.13B
BVSBioventus Inc942.04M
JNJJohnson & Johnson667.30B
OFIXOrthofix Medical Inc298.77M
MDXGMimedx Group Inc483.82M

Held by

AUM
TickerCompanyAUM
BINVBrandes International ETFAUM: 580.22M
DFICDimensional International Core Equity 2 ETF-
AVDEAvantis International Equity ETFAUM: 19.73B
DFAXDimensional World ex U.S. Core Equity 2 ETF-
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
APIEActivePassive International Equity ETFAUM: 1.13B
DTECALPS Disruptive Technologies ETFAUM: 71.78M
DFSIDimensional International Sustainability Core 1 ETF-
TIIVAAM Todd International Intrinsic Value ETFAUM: 31.97M
AVSDAvantis Responsible International Equity ETFAUM: 379.33M

News

latest 14 of 206
  • After Smith+Nephew's $34 Billion Merger Collapse, This Wound Care Stock Is Worth a Look (NASDAQ: MDWD) (FinanceWire)
  • UBS sees attractive risk/reward in three European medtech into Q3 results (Investing.com)
  • Smith+Nephew's revolutionary CARTIHEAL AGILI-C Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal (GlobeNewswire)
  • Smith+Nephew lanza en Europa el innovador implante de reparacion de cartilago CARTIHEAL AGILI-C, que sera protagonista en el Congreso ICRS de Portugal (GlobeNewswire)
  • Smith+Nephew lancia in Europa CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine, che sara presentato all'ICRS Summit in Portogallo. (GlobeNewswire)
  • Loading…
  • Smith & Nephew PLC's Dividend Analysis (GuruFocus.com)
  • GS adds four European stocks to conviction list as earnings catalysts emerge (Investing.com)
  • MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management (GlobeNewswire)
  • Smith+Nephew launches the new EVOS PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management (GlobeNewswire)
  • Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK Total Knee System (GlobeNewswire)
  • Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026 (GlobeNewswire)
  • Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds (ACCESSWIRE)
  • Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-08-040.9460.9390.7043,0983,4596
2025S22026-03-021.1791.1550.7633,2032,7744
2025S12025-08-050.8580.7900.6722,9612,9255
2024S22025-02-250.9380.9200.4502,9832,9623
2024S12024-08-010.7520.7860.4912,8272,8255
2023S22024-02-270.9590.9700.2072,8132,8003
2023Q22023-08-030.700--1,3791,363-
2026S2--1.161--3,3145
2027S1--1.030---1
2027S2--1.410---1
2028S1--1.310--3,5481
2028S2--1.520--3,8881

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY2.0442.0251.3745,1385,120
2020FY1.2921.2641.0304,5604,615
2021FY1.6181.6531.1945,2125,222
2022FY1.6361.5540.5115,2155,200
2023FY1.6561.6450.6055,5495,546
2024FY1.6861.6600.9415,8105,773
2025FY2.0401.9861.4426,1646,136
2026FY-2.139--6,425
2027FY-2.310--6,733
2028FY-2.575--7,094
2029FY-2.822--7,484
2030FY-3.015--7,822

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-11-093003,3143,2893,336
2026S2S2026-11-043013,3143,2893,336
2026S2S2026-10-192013,3223,3083,336
2026S2S2026-08-262023,3223,3083,336
2026S2S2026-08-052023,3613,3363,386
2026S2S2026-08-042013,3833,3813,386
2026S2S2026-06-262013,3833,3813,386
2026S2S2026-06-232013,3833,3803,386
2026S2S2026-05-212013,4003,3803,421
2026S2S2026-05-062003,4203,3803,460
2026S2S2026-03-021003,4603,4603,460
2026S2R2026-11-042010.860.840.87
2026S2R2026-08-041000.960.960.96
2026S2R2026-07-081000.960.960.96

Estimate history

EPS, annual1.7721.5111.3741.031.1940.5110.6050.9411.435
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual4816.094895.7095159.2694595.4725211.3795211.7825570.5085812.4456178.404
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual436.828437.026436.878437.893439.096435.075435.936436.752424.662
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue6,286.696,178.405,812.445,570.515,211.785,211.384,595.475,159.274,895.71
Cost of Goods Sold Incl. D&A1,998.492,039.761,955.821,855.161,738.931,743.791,621.521,536.331,467.51
Gross Profit4,288.204,138.653,856.623,715.353,472.863,467.592,973.963,622.943,428.19
Selling, General and Administrative Excl. Other3,216.633,078.182,882.212,774.712,685.342,685.682,411.622,590.682,392.95
Research and Development302.36294.69288.12300.16299.81316.96281.17269.11236.60
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1,071.571,060.47974.41940.63787.51781.91562.341,032.261,035.25
Interest Expense157.68141.33150.06132.5179.9579.9962.4865.2758.90
Unusual Expense260.12231.54295.12495.91326.80174.98230.78197.82154.74
Net Income Before Taxes676.71667.56508.21321.24375.77576.93233.80745.07790.66
Income Taxes161.65154.3686.0427.1011.9961.99-203.57143.59117.80
Consolidated Net Income633.63626.46412.17264.02222.86523.94451.48602.48661.88
Net Income From Continuing Operations633.63626.46412.17264.02222.86523.94451.48602.48661.88
Net Income633.63626.46412.17264.02222.86523.94451.48602.48661.88
EPS (Recurring)1.901.811.411.401.031.471.401.691.76
EPS (Basic, Before Extraordinaries)1.481.450.940.610.511.191.031.381.52
EPS (Diluted)1.471.440.940.600.511.191.031.371.51
EBITDA1,670.321,635.811,529.641,469.671,335.181,344.841,111.581,530.311,461.52
Non-Operating Income (Expense)22.95-20.05-21.019.03-5.0049.99-35.27-24.10-30.95
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense41.9332.3330.0129.3632.3833.2121.2226.0328.30
Price To Earnings Ratio20.8720.8735.2153.8923.6428.8241.6734.8024.22
Price To Sales Ratio2.062.321.852.142.252.924.024.093.34
Gross Margin68.2166.9966.3566.7066.6366.5464.7170.2270.02
Operating Margin17.0517.1616.7616.8915.1115.0012.2420.0121.15
Net Margin10.0810.147.094.744.2810.059.8211.6813.52
Shares Outstanding424.66424.66436.75435.94435.07439.10437.89436.88437.03
Market Capitalization12,940.5512,940.5510,716.6611,869.5011,685.0015,207.4618,437.8220,990.5816,312.56

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue3,095.703,190.992,987.732,984.682,827.892,818.472,751.302,612.93
Cost of Goods Sold Incl. D&A900.621,097.87877.85911.51853.27895.10841.29766.39
Gross Profit2,195.082,093.122,109.872,073.161,974.621,923.371,910.011,846.54
Selling, General and Administrative Excl. Other1,716.281,500.351,665.901,594.901,590.501,474.821,593.021,485.82
Research and Development149.94152.43144.29152.09137.04173.21167.05170.86
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income478.80592.77443.97478.27384.12448.55316.99360.71
Interest Expense82.9774.7281.7391.0582.0377.1062.3947.96
Unusual Expense30.99229.1411.10149.0856.02298.3740.25152.88
Net Income Before Taxes374.84301.86366.28253.14255.0889.11232.46170.86
Income Taxes76.9784.6869.6247.0339.01-12.0139.25-14.99
Consolidated Net Income302.87330.76295.64198.11214.0791.11173.0945.96
Net Income From Continuing Operations302.87330.76295.64198.11214.0791.11173.0945.96
Net Income302.87330.76295.64198.11214.0791.11173.0945.96
EPS (Recurring)0.751.130.690.690.580.680.460.35
EPS (Basic, Before Extraordinaries)0.710.770.680.450.490.210.400.11
EPS (Diluted)0.700.760.670.450.490.210.400.11
EBITDA778.67891.64719.44850.48657.21835.03615.87668.47
Non-Operating Income (Expense)10.0012.9515.1415.019.0016.0218.1110.99
Stock Option Compensation Expense25.4916.4415.8915.0115.0015.0215.4913.76
Price To Earnings Ratio20.8729.0232.6035.2141.1453.8963.7123.64
Price To Sales Ratio2.062.302.231.861.912.152.622.24
Gross Margin70.9165.5970.6269.4669.8368.2469.4270.67
Operating Margin15.4718.5814.8616.0213.5815.9111.5213.80
Net Margin9.7810.379.906.647.573.236.291.76
Shares Outstanding424.66424.66436.75436.75435.94435.94435.07435.07
Market Capitalization12,940.5513,924.9613,401.3010,716.6610,803.4411,869.5014,031.6511,685.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments557.00619.00302.00350.001,290.001,762.00277.00365.00169.00
Short Term Receivables1,330.001,288.001,241.001,225.001,211.001,130.001,253.001,248.001,176.00
Inventories2,117.002,387.002,395.002,205.001,844.001,691.001,614.001,395.001,304.00
Other Current Assets99.00127.0092.0076.0079.0081.0075.0069.0082.00
Total Current Assets4,103.004,421.004,030.003,856.004,424.004,664.003,219.003,077.002,731.00
Net Property, Plant & Equipment1,638.001,422.001,470.001,455.001,513.001,449.001,323.001,062.001,049.00
Total Investments and Advances286.0016.0024.0058.00198.00117.00110.00139.00139.00
Intangible Assets3,990.004,058.004,102.004,267.004,387.004,414.004,356.003,547.003,742.00
Deferred Tax Assets347.00350.00274.00177.00201.00202.00150.00126.00127.00
Other Assets93.0087.0087.00153.00197.00166.00141.00108.0078.00
Total Assets10,457.0010,354.009,987.009,966.0010,920.0011,012.009,299.008,059.007,866.00
Short Term Debt Incl. Current Port. of LT Debt150.0063.00765.00160.00491.00337.0072.00164.0027.00
Accounts Payable1,160.001,082.001,016.001,029.001,043.00891.00941.00854.00873.00
Income Tax Payable194.00232.00218.00214.00222.00206.00243.00223.00233.00
Other Current Liabilities91.00154.00272.00312.00375.00254.00308.00224.00213.00
Total Current Liabilities1,595.001,531.002,271.001,715.002,131.001,688.001,564.001,465.001,346.00
Long Term Debt3,177.003,258.002,319.002,712.002,848.003,353.001,975.001,301.001,423.00
Provision for Risks Charges166.00174.00136.00154.00162.00457.00350.00267.00228.00
Deferred Tax Liabilities40.0031.009.0036.00144.00141.00167.0099.0097.00
Other Liabilities190.0095.0035.0090.0067.0094.00102.0053.00128.00
Total Liabilities5,168.005,089.004,770.004,707.005,352.005,733.004,158.003,185.003,222.00
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5,289.005,265.005,217.005,259.005,568.005,279.005,141.004,874.004,644.00
Total Shareholders Equity5,289.005,265.005,217.005,259.005,568.005,279.005,141.004,874.004,644.00
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5,289.005,265.005,217.005,259.005,568.005,279.005,141.004,874.004,644.00
Total Liabilities & Stockholders Equity10,457.0010,354.009,987.009,966.0010,920.0011,012.009,299.008,059.007,866.00
Book Value Per Share12.4512.0511.9712.0912.6812.0511.7711.1510.63
Tangible Book Value Per Share3.062.762.562.282.691.981.803.042.06
Full-Time Employees18,36218,45619,55120,12218,36917,91417,63716,37715,933
Price to Book Ratio2.522.062.272.152.733.504.093.353.70
Return on Assets6.024.052.652.134.784.456.948.3110.19
Return on Equity11.877.865.044.129.668.6712.0313.9118.02
Return on Invested Capital7.404.843.502.806.235.238.4710.7212.78
Quick Ratio1.251.330.720.961.211.761.031.151.06
Current Ratio2.572.891.772.252.082.762.062.102.03

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income790.65780.82498.21291.12234.85585.93247.91746.08779.68
Depreciation596.26575.34555.23529.04547.66562.93549.24498.05426.28
Other Funds (Non Cash)-167.50-195.4641.02123.48220.86-117.9992.72-95.39-85.85
Funds from Operations1,219.411,160.711,094.46943.641,003.381,030.88889.871,148.741,120.10
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital111.00127.30-107.05-333.29-534.67-149.9861.4727.11-188.68
Cash from Operating Activities1,330.421,288.00987.42610.36468.71880.90951.341,175.85931.42
Capital Expenditures-481.04-434.01-381.16-428.66-357.78-407.95-446.45-409.69-346.41
Net Assets From Acquisitions-221.80-9.02-186.08-21.08-112.93-284.97-171.32-872.60-28.95
Sale of Fixed Assets and Businesses25.7538.090.000.000.000.000.000.000.00
Purchase or Sale of Investments-1.99-2.00-2.000.00-2.00-2.00-2.0223.10-3.99
Purchase of Investments-1.99-2.00-2.000.00-2.00-2.00-2.020.00-3.99
Sale Or Maturity of Investments0.000.000.000.000.000.000.0023.100.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-679.09-406.95-569.24-449.74-472.71-694.92-619.78-1,259.19-379.36
Cash Dividends Paid-329.85-330.77-327.14-328.27-326.80-328.96-330.55-319.32-320.46
Change in Capital Stock-602.12-491.151.000.00-151.9114.00-5.04-52.22-34.94
Repurchase of Common Pref Stock-616.07-503.170.000.00-157.900.00-16.12-63.26-47.92
Sale of Common Pref Stock13.9412.031.000.006.0014.0011.0911.0512.98
Proceedsfrom Stock Options13.9412.031.000.006.0014.0011.0911.0512.98
Issuance or Reduction of Debt, Net413.98-86.20295.12175.68-395.76-266.971,557.02426.76-6.99
Change in Long Term Debt488.09-90.211,000.420.0010.990.001,562.06552.28-1.00
Issuance of Long Term Debt577.760.001,000.420.00484.700.001,965.171,295.34369.37
Reduction of Long Term Debt-89.66-90.210.000.00-473.710.00-403.11-743.06-370.37
Net Financing Active Other Cash Flow-3.951.000.004.023.00-4.007.05-2.01-7.99
Other Financing Activities Uses-4.950.000.000.000.00-4.000.00-2.01-7.99
Cash from Financing Activities-575.53-957.23-86.04-200.78-925.43-644.921,173.057.03-370.37
Exchange Rate Effect0.8512.03-15.01-4.02-10.99-7.001.010.00-3.99
Net Change in Cash76.65-64.15317.13-44.17-940.42-465.941,505.62-76.31177.70
Free Cash Flow849.38853.99606.25181.70110.93472.94504.90766.16599.98
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow24.8927.3738.57--105.56106.0647.1758.57
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments758.17557.00675.41619.00568.00302.00
Short Term Receivables1,528.411,330.001,482.701,288.001,399.001,241.00
Inventories2,124.692,117.002,464.842,387.002,491.002,395.00
Other Current Assets-99.00-127.00-92.00
Total Current Assets4,411.264,103.004,622.954,421.004,458.004,030.00
Net Property, Plant & Equipment1,623.931,638.001,434.741,422.001,441.001,470.00
Total Investments and Advances151.84286.0035.9716.0024.0024.00
Intangible Assets4,369.033,990.004,069.444,058.004,216.004,102.00
Deferred Tax Assets253.39347.00400.65350.00319.00274.00
Other Assets264.4593.00118.9087.0084.0087.00
Total Assets11,073.9110,457.0010,682.6510,354.0010,542.009,987.00
Short Term Debt Incl. Current Port. of LT Debt576.17150.00156.8663.00380.00765.00
Accounts Payable1,255.911,177.001,096.041,128.001,024.001,055.00
Income Tax Payable161.89194.00228.80232.00221.00218.00
Other Current Liabilities68.3874.0057.95108.00152.00233.00
Total Current Liabilities2,062.341,595.001,539.651,531.001,777.002,271.00
Long Term Debt3,229.763,177.003,294.123,258.003,275.002,319.00
Deferred Tax Liabilities40.2240.0041.9631.0036.009.00
Other Liabilities372.05190.0095.9295.0096.0035.00
Total Liabilities5,865.265,168.005,151.495,089.005,337.004,770.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5,208.655,289.005,531.165,265.005,205.005,217.00
Total Shareholders Equity5,208.655,289.005,531.165,265.005,205.005,217.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5,208.655,289.005,531.165,265.005,205.005,217.00
Total Liabilities & Stockholders Equity11,073.9110,457.0010,682.6510,354.0010,542.009,987.00
Book Value Per Share12.2612.4512.6612.0511.9411.97
Tangible Book Value Per Share1.983.063.352.762.272.56
Price to Book Ratio2.522.592.542.062.072.27
Return on Assets5.826.024.654.052.992.65
Return on Equity11.8011.879.207.865.855.04
Return on Invested Capital3.593.913.352.322.521.21
Quick Ratio1.111.251.401.331.110.72
Current Ratio2.142.573.002.892.511.77

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income379.84410.81365.27245.20253.0878.02
Depreciation299.87296.38275.46282.23273.09228.77
Other Funds (Non Cash)-56.98-110.52-83.7575.03-34.01145.29
Funds from Operations622.74596.68556.98602.46492.15452.08
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-172.93283.93-157.41147.02-254.0842.95
Cash from Operating Activities449.81880.61399.57749.48238.07495.04
Capital Expenditures-189.92-291.12-140.25-209.16-172.05-259.47
Net Assets From Acquisitions-220.91-0.89-8.07-0.05-186.06-5.93
Sale of Fixed Assets and Businesses0.0025.7512.110.000.000.00
Purchase or Sale of Investments0.00-1.990.00-0.00-2.000.00
Purchase of Investments0.00-1.990.00-0.00-2.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-410.83-268.26-136.22-209.21-360.11-265.40
Cash Dividends Paid-204.91-124.94-203.82-125.12-202.06-125.13
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-112.95-489.171.010.001.00-1.01
Repurchase of Common Pref Stock-115.95-500.120.000.000.000.00
Sale of Common Pref Stock3.0010.951.010.001.00-1.01
Proceedsfrom Stock Options3.0010.951.010.001.00-1.01
Issuance or Reduction of Debt, Net513.78-99.8014.13-305.02600.19175.22
Change in Long Term Debt577.76-89.660.001,000.560.000.00
Issuance of Long Term Debt577.760.000.001,000.560.000.00
Reduction of Long Term Debt0.00-89.660.000.000.000.00
Net Financing Active Other Cash Flow-10.006.04-5.050.000.008.03
Other Financing Activities Uses-10.005.05-5.050.000.004.03
Cash from Financing Activities156.93-732.46-218.96-458.16372.12-113.70
Exchange Rate Effect1.00-0.1512.11-10.01-5.002.03
Net Change in Cash196.92-120.2756.5172.10245.08117.96
Free Cash Flow259.89589.49259.32540.3266.02235.57
Price to Free Cash Flow24.8927.3528.2538.76--

Revenue breakdown

Advanced Wound Management2024: 1.68B 2025: 1.79B
Orthopaedics, Sports Medicine and Ear Nose and Throat2024: 4.13B 2025: 4.37B
United Kingdom2024: 5.81B 2025: 6.16B
Advanced Wound Management2024: 1.68B 2025: 1.79B
Orthopaedics2024: 2.31B 2025: 2.44B
Sports Medicine & ENT2024: 1.82B 2025: 1.93B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.05%4.4M418.3M1.46M
2026-10-150.97%4.0M418.3M1.59M
2026-09-301.11%4.7M418.3M1.65M
2026-09-151.16%4.8M418.3M1.72M
2026-08-311.49%6.2M418.3M1.55M
2026-08-141.17%4.9M418.3M1.47M
2026-07-311.21%5.1M419.5M1.50M
2026-07-151.07%4.5M420.4M1.36M
2026-06-300.88%3.7M421.3M1.23M
2026-06-150.76%3.2M423.4M1.08M
2026-05-290.79%3.4M424.7M1.07M
2026-05-150.76%3.2M425.9M1.01M
2026-04-300.69%3.0M426.4M912.97K
2026-04-150.72%3.1M426.1M866.49K
2026-03-310.80%3.4M426.1M891.93K
2026-03-130.83%3.5M424.1M871.61K
2026-02-270.74%3.1M424.1M763.08K
2026-02-130.73%3.1M424.0M730.18K
2026-01-300.87%3.7M424.0M701.14K
2026-01-150.75%3.2M424.0M621.25K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0014.6017.000.004.3980.000.000.916-0.1830.008
call17.5012.1015.500.004.6930.000.000.897-0.1760.009
call20.0010.0011.500.002.4590.000.000.884-0.1470.009
call22.507.309.200.001.9150.000.000.845-0.1550.012
call25.004.407.000.001.8510.000.000.805-0.1390.013
call30.000.751.702.000.61413.000.000.597-0.1620.019
call35.000.000.200.170.6384020.000.129-0.0350.011
call40.000.004.100.001.1210.000.000.085-0.0470.008
put15.000.001.350.004.4590.000.00-0.084-0.1840.008
put17.500.001.350.003.6940.000.00-0.102-0.1770.009
put20.000.002.300.003.0300.000.00-0.125-0.1670.010
put22.500.002.500.002.4390.000.00-0.154-0.1550.012
put25.000.001.150.361.8844.000.00-0.195-0.1390.013
put30.000.003.701.002.0653.000.00-0.403-0.1610.019
put35.002.006.500.002.0090.000.00-0.870-0.0360.010
put40.006.5011.400.002.6140.000.00-0.914-0.0450.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-04SEC
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-04SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-08SEC
2026-10-0525-NSESEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-17CERTSEC
2026-09-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-16SEC
2026-09-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-16SEC
2026-09-118-A12BSEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-11SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-10424B5SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-09FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-08424B5SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-21SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-18SEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GOLDMAN SACHS GROUP INC0.72%
River Road Asset Management, LLC0.70%
BRANDES INVESTMENT PARTNERS, LP0.51%
DIMENSIONAL FUND ADVISORS LP0.42%
LMR Partners LLP0.42%
CAUSEWAY CAPITAL MANAGEMENT LLC0.37%
WELLS FARGO & COMPANY/MN0.32%
MORGAN STANLEY0.28%
TODD ASSET MANAGEMENT LLC0.26%
NORTHERN TRUST CORP0.23%

Funds

Fund% owned
Strategic Advisers U.S. Total Stock Fund0.08%
Dimensional International Core Equity 2 ETF0.07%
INTERNATIONAL CORE EQUITY 2 PORTFOLIO0.07%
Avantis International Equity ETF0.06%
Brandes International ETF0.06%
JNL Multi-Manager Small Cap Value Fund0.05%
AMG River Road Mid Cap Value Fund0.04%
Dimensional World ex. U.S. Core Equity 2 ETF0.04%
Buffalo International Fund0.04%
AMG River Road Small-Mid Cap Value Fund0.04%

OakChart. SNN. Cached 15 minutes.

Some panels did not load: insider.